You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-Angiogenesis

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Anti-angiogenesis Combined With PD-1/PD-L1 Therapy in Advanced

Not yet recruiting
  • Carcinoma, Hepatocellular
    • (no location specified)
    May 16, 2022

    Nephrotoxicity Trial (Huaier Granule, VEGFR-TKIs)

    Not yet recruiting
    • Nephrotoxicity
    • (no location specified)
    Jan 5, 2023

    NSCLC Trial in Tianjin (Tislelizumab, Pemetrexed, Bevacizumab)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Institute and Hospital
    Jul 11, 2022

    Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced

    Recruiting
    • Esophageal Neoplasms
    • an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor
    • Zhengzhou, Henan, China
      The First Affiliated Hospital of Zhengzhou University
    Apr 21, 2022

    NSCLC, Minimal Residual Disease, Immunotherapy Trial in Shanghai (sintilimab combined with anlotinib, sintilimab monotherapy)

    Recruiting
    • Non-small Cell Lung Cancer
    • +3 more
    • sintilimab combined with anlotinib
    • sintilimab monotherapy
    • Shanghai, China
      Shanghai Chest Hospital
    Jul 14, 2022

    Non Small Cell Lung Cancer Trial in Tianjin (Osimertinib, Bevacizumab Biosimilar IBI305, Carboplatin)

    Recruiting
    • Non Small Cell Lung Cancer
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Institute and Hospital
    Aug 18, 2022

    Melanoma, Malignant Melanoma, Stage IIIA Melanoma Trial in Orange (procedure, other, drug)

    Completed
    Has Results
    • Melanoma
    • +4 more
    • therapeutic conventional surgery
    • +3 more
    • Orange, California
      Chao Family Comprehensive Cancer Center
    Dec 30, 2020

    Therapeutic Combination in Advanced or Metastatic Kidney Cancer

    Not yet recruiting
    • Renal Cell Carcinoma
    • +2 more
    • Blood collection
    • Tumour samples
    • Paris, France
    • +1 more
    Mar 9, 2022

    Colorectal Cancer Trial in United States (hydroxychloroquine)

    Completed
    Has Results
    • Colorectal Cancer
    • Camden, New Jersey
    • +3 more
    Sep 20, 2021

    Retinal Pigment Epithelium Detachment in Neovascular Age-related

    Active, not recruiting
    • Neovascular Age-related Macular Degeneration
    • Anti-vascular endothelial growth factor therapy
    • Krasnodar, Russian Federation
      The S.N. Fyodorov Eye Microsurgery State Institution
    Jan 12, 2022

    Non-small-cell Lung Cancer Trial in Shanghai (gefitinib combined with chemo, gefitinib combined with apatinib, gefitinib single

    Unknown status
    • Non-small-cell Lung Cancer
    • gefitinib combined with chemotherapy
    • +2 more
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital;
    Jul 31, 2020

    Breast Cancer, Angiogenesis Trial in Burlington (Aspirin)

    Completed
    • Breast Cancer
    • Angiogenesis
    • Burlington, Vermont
      University of Vermont
    Sep 15, 2020

    Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy

    Unknown status
    • Glioblastoma
    • Fuzhou, Fujian, China
      Fuzhou General Hospital
    Feb 29, 2020

    Sintilimab and Anlotinib in Combination With Chemo Trial in Xi'an (Sintilimab and anlotinib in combination with chemo)

    Completed
    • Sintilimab and Anlotinib in Combination With Chemotherapy
    • Sintilimab and anlotinib in combination with chemotherapy
    • Xi'an, Shanxi, China
    • +1 more
    Aug 27, 2023

    Adenocarcinoma of the Lung Trial in China (Camrelizumab, Albumin Paclitacxel, Apatinib)

    Not yet recruiting
    • Adenocarcinoma of the Lung
    • Fuzhou, Fujian, China
    • +4 more
    Jul 1, 2020

    Lung Cancer Trial in Hangzhou (sintilimab and anlotinib)

    Active, not recruiting
    • Lung Cancer
    • sintilimab and anlotinib
    • Hangzhou, Zhejiang, China
      Zhejiang Cancer Hospital
    Jun 29, 2022

    Hepatocellular Carcinoma Trial in Yichang (Sintilimab)

    Recruiting
    • Hepatocellular Carcinoma
    • Yichang, Hubei, China
      Department of Medical Oncology, Central Hospital of Yichang City
    Sep 1, 2023

    Gastric Cancer Trial in Jinan (SHR1210, Apatinib, S1)

    Recruiting
    • Gastric Cancer
    • Jinan, Shandong, China
      Qilu hospital of Shandong univertisy
    Mar 30, 2022

    Breast Cancer Stage II Trial in Xi'an (Anlotinib)

    Recruiting
    • Breast Cancer Stage II
    • Xi'an, Shannxi Province, China
      Xijing Hospital Affiliated to Air Force Military Medical Univers
    Sep 25, 2022

    NSCLC Trial in Yichang (Sindillimab)

    Completed
    • Non-small Cell Lung Cancer
    • Yichang, Hubei, China
      Department of Medical Oncology, Central Hospital of Yichang City
    Mar 29, 2023

    Unresectable Locally Advanced or Metastatic Pancreatic Cancer Trial in Shanghai (surufatinib, KN046, gemcitabine)

    Not yet recruiting
    • Unresectable Locally Advanced or Metastatic Pancreatic Cancer
    • Shanghai, Shanghai, China
      Zhongshan Hospital
    Apr 16, 2023

    Metastatic Colorectal Cancer Trial in Fuzhou (Thalidomide, TAS-102)

    Recruiting
    • Metastatic Colorectal Cancer
    • Fuzhou, Fujian, China
    • +5 more
    Mar 4, 2022

    Curcumin, Homotaurine, Vitamin D3 on Human Vitreous in Diabetic

    Completed
    • Diabetic Retinopathy
    • curcumin, homotaurine, vitamin D3
    • control
    • Campobasso, Italy
      University of Molise
    May 6, 2020

    Sarcoma Trial in Shanghai (SHR-1210 Plus Apatinib, ADM Plus IFO or IFO Alone)

    Recruiting
    • Sarcoma
    • SHR-1210 Plus Apatinib
    • ADM Plus IFO or IFO Alone
    • Shanghai, Shanghai, China
      Shanghai Jiao Tong University Affiliated Sixth People's Hospital
    Jul 25, 2019

    Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - NSCLC Trial in Kansas City, Overland Park, Lee's Summit (Cabozantinib,

    Not yet recruiting
    • Lung Cancer
    • +3 more
    • Kansas City, Kansas
    • +3 more
    May 12, 2023